Home > News > pSivida Limited Describes Strategy for Further Clinical Trials
February 18th, 2005
pSivida Limited Describes Strategy for Further Clinical Trials
Abstract:
Dr. Aston discusses the importance of the recently-announced successful Phase IIa clinical trials of the company's lead product, BrachySil(TM) for liver cancer, as well as the company's plans for clinical trials and commercialization of the product. In the most recent trial, it was demonstrated that BrachySil(TM) is safe and effective in tumor regression with increased efficacy.
Source:
businesswire
Bookmark:
| Related News Press |
Possible Futures
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||